Annual report
4885.TEDINET S100P2VN
Period2021-06-01 → 2022-05-31
Filed2022-08-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 96
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.7bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥4.9bn | 2020-06-01 → 2021-05-31 | Standalone | Net sales |
| Revenue | ¥5.3bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.4bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.4bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.5bn | 2017-06-01 → 2018-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥437m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Operating income | ¥369m | 2020-06-01 → 2021-05-31 | Standalone | Operating income |
| Ordinary income | ¥423m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥339m | 2020-06-01 → 2021-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥272m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥278m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥91m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥108m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥20m | 2017-06-01 → 2018-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥426m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥200m | 2020-06-01 → 2021-05-31 | Standalone | Income before income taxes |
| Net income (owners) | ¥32m | 2019-06-01 → 2020-05-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥29m | 2018-06-01 → 2019-05-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥456m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥181m | 2020-06-01 → 2021-05-31 | Standalone | Profit loss |
| Net income | ¥34m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥112m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥88m | 2017-06-01 → 2018-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.8bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥4.6bn | at 2021-05-31 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.7bn | at 2018-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2022-05-31 | Standalone | Liabilities |
| Total liabilities | ¥3.3bn | at 2021-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31 | Standalone | Net assets |
| Net assets / equity | ¥252m | at 2020-05-31d | Standalone | Net assets |
| Net assets / equity | ¥182m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥179m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥71m | at 2018-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥865m | at 2022-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2021-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥865m | at 2022-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2021-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥881m | at 2020-05-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥614m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥525m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥488m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥89m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥342m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥176m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥58m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥137m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥311m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥484m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥311m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥42m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥23m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥123.79 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.24 | 2020-06-01 → 2021-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.75 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.16 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.46 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.99 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-219.58 | 2017-06-01 → 2018-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥112.56 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.97 | 2020-06-01 → 2021-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥19 | 2021-06-01 → 2022-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-06-01 → 2021-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2018-06-01 → 2019-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2017-06-01 → 2018-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥450.37 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥363.93 | at 2021-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥101.92 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.2 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥89.32 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.52 | at 2018-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 5.3% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 3.9% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 1.5% | at 2018-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 30.3% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 22.8% | 2020-06-01 → 2021-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.9% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 89.6% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,095,500 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2021-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 775,000 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,010,000 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,010,000 | at 2018-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 197 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 195 | at 2021-05-31 | Standalone | Number of employees |
| Employees | 196 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 199 | at 2019-05-31d | Standalone | Number of employees |
| Employees | 199 | at 2018-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 53
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥1.3bn |
| Chemical Products Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥39m |
| Chemical Products Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥55m |
| Chemical Products Businessreportable segment | employees | at 2022-05-31 | 50 pure |
| Chemical Products Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥1.9bn |
| Chemical Products Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥1.9bn |
| Chemical Products Businessreportable segment | segment assets | at 2022-05-31 | ¥1.2bn |
| Chemical Products Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | −¥16m |
| Healthy Food Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥116m |
| Healthy Food Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥11m |
| Healthy Food Businessreportable segment | employees | at 2022-05-31 | 27 pure |
| Healthy Food Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥824m |
| Healthy Food Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥824m |
| Healthy Food Businessreportable segment | segment assets | at 2022-05-31 | ¥399m |
| Healthy Food Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥1m |
| Pharmaceutical Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥58m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥36m |
| Pharmaceutical Businessreportable segment | employees | at 2022-05-31 | 44 pure |
| Pharmaceutical Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥2.9bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥2.9bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-05-31 | ¥2.0bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥452m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥213m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥101m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥437m |
| Reconciling Itemsreconciling | segment assets | at 2021-05-31 | ¥1.3bn |
| Chemical Products Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥15m |
| Chemical Products Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥67m |
| Chemical Products Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥1.7bn |
| Chemical Products Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥1.7bn |
| Chemical Products Businessreportable segment | segment assets | at 2021-05-31 | ¥1.2bn |
| Chemical Products Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | −¥61m |
| Healthy Food Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥4m |
| Healthy Food Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥22m |
| Healthy Food Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥800m |
| Healthy Food Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥800m |
| Healthy Food Businessreportable segment | segment assets | at 2021-05-31 | ¥376m |
| Healthy Food Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | −¥44m |
| Pharmaceutical Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥16m |
| Pharmaceutical Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥35m |
| Pharmaceutical Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2021-05-31 | ¥1.7bn |
| Pharmaceutical Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-06-01 → 2021-05-31 | ¥35m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-06-01 → 2021-05-31 | ¥124m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-06-01 → 2021-05-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-06-01 → 2021-05-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-05-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-06-01 → 2021-05-31 | ¥369m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,194
| Item | Context | Value | Unit |
|---|---|---|---|
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.692 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.018 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 197 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 38.5 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8.3 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5079000 | JPY |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 48 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 44 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 2 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000HealthyFoodBusinessReportableSegmentMember | 27 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000HealthyFoodBusinessReportableSegmentMember | 36 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 50 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 6 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 76 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 4 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 197 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 48 | |
| Research and development expenses research and development activities | CurrentYearDuration | 29027000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 17480000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36350-000HealthyFoodBusinessReportableSegmentMember | 1052000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 10494000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 213342000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 37316000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36350-000HealthyFoodBusinessReportableSegmentMember | 107651000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 20114000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 48260000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4095500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4095500 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4095500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4095500 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 21 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 8 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 9 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 3597 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 3658 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 1059 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 1163 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |